RT Journal Article
SR Electronic
T1 Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus.
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 1858
OP 1866
VO 29
IS 9
A1 Hiroshi Kobayashi
A1 Osamu Hosono
A1 Tsuneyo Mimori
A1 Hiroshi Kawasaki
A1 Nam Hoang Dang
A1 Hirotoshi Tanaka
A1 Chikao Morimoto
YR 2002
UL http://www.jrheum.org/content/29/9/1858.abstract
AB OBJECTIVE: CD26 is the cell surface activation antigen with dipeptidyl peptidase IV (DPPIV) enzyme activity at the extracellular domain that is preferentially expressed on memory T cells and has a role in T cell immune responses. The soluble form of CD26 is present in serum and recombinant soluble CD26 (rsCD26) can enhance in vitro antigen-specific T cell responses. To determine the role of soluble CD26 (sCD26) in the pathophysiology of patients with systemic lupus erythematosus (SLE), we measured levels of sCD26 and its specific DPPIV activity in serum. METHODS: Serum sCD26 levels and DPPIV activity were measured by sandwich ELISA in 53 patients with SLE and 54 healthy controls. Serum sCD26 was identified by immunoprecipitation and immunoblot analysis. Expression of CD26 on T cells was analyzed by flow cytometry. RESULTS: Serum levels of sCD26 and its specific DPPIV activity were significantly decreased in SLE and were inversely correlated with SLE disease activity index score, but not with clinical variables or clinical subsets of SLE. Close correlation between sCD26/DPPIV and disease activity was observed in the longitudinal study. CONCLUSION: Serum levels of sCD26 may be involved in the pathophysiology of SLE, and appear to be useful as a new disease activity measure for SLE.